In addition to the induction of an irreversible mitotic block, eribulin has been shown to impact tumor vascular remodeling [10] and inhibition of epithelial-to-mesenchymal transition and metastasis in experimental models [11] which has been implicated in therapeutic resistance to cancer drugs including growth factor receptor and PI3K inhibitors [12]. This evidence concerns the gene PIK3CA and cancer.